US · Healthcare · Biotechnology
EPS came in at -526.11 against a street estimate of -0.51 — a miss of 102777.3%.
with an average price target of $25.30.
| Fund | Stake |
|---|---|
| Cormorant Asset Management, LLC | 22.32% |
| Deerfield Management Co | 6.10% |
| Omega Fund Management LLC | 4.11% |
| Alphabet Inc | 3.52% |
| EcoR1 Capital, LLC | 3.52% |
| Wellington Management Company LLP | 3.52% |
| Enavate Sciences GP, LLC | 3.28% |
| Citadel Advisors Llc | 3.16% |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BridgeBio Oncology Therapeutics, Inc. — free to start.
Google PlayApp StoreData updated 2026-08-05.